Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

726 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.
Lewin J, Khamly KK, Young RJ, Mitchell C, Hicks RJ, Toner GC, Ngan SY, Chander S, Powell GJ, Herschtal A, Te Marvelde L, Desai J, Choong PF, Stacker SA, Achen MG, Ferris N, Fox S, Slavin J, Thomas DM. Lewin J, et al. Among authors: young rj. Br J Cancer. 2014 Dec 9;111(12):2254-61. doi: 10.1038/bjc.2014.537. Epub 2014 Oct 16. Br J Cancer. 2014. PMID: 25321190 Free PMC article. Clinical Trial.
Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial.
Lim AM, Rischin D, Fisher R, Cao H, Kwok K, Truong D, McArthur GA, Young RJ, Giaccia A, Peters L, Le QT. Lim AM, et al. Among authors: young rj. Clin Cancer Res. 2012 Jan 1;18(1):301-7. doi: 10.1158/1078-0432.CCR-11-2295. Epub 2011 Nov 17. Clin Cancer Res. 2012. PMID: 22096023 Free PMC article. Clinical Trial.
Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer.
Le QT, Fisher R, Oliner KS, Young RJ, Cao H, Kong C, Graves E, Hicks RJ, McArthur GA, Peters L, O'Sullivan B, Giaccia A, Rischin D. Le QT, et al. Among authors: young rj. Clin Cancer Res. 2012 Mar 15;18(6):1798-807. doi: 10.1158/1078-0432.CCR-11-2094. Epub 2012 Mar 1. Clin Cancer Res. 2012. PMID: 22383739 Free PMC article. Clinical Trial.
Treatment response in the neck: p16+ versus p16- oropharyngeal cancer.
Mak D, Hicks RJ, Rischin D, Solomon B, Peters L, Bressel M, Young RJ, Corry J. Mak D, et al. Among authors: young rj. J Med Imaging Radiat Oncol. 2013 Jun;57(3):364-72. doi: 10.1111/1754-9485.12024. Epub 2013 Jan 30. J Med Imaging Radiat Oncol. 2013. PMID: 23721148 Clinical Trial.
Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome.
Lim AM, Do H, Young RJ, Wong SQ, Angel C, Collins M, Takano EA, Corry J, Wiesenfeld D, Kleid S, Sigston E, Lyons B, Fox SB, Rischin D, Dobrovic A, Solomon B. Lim AM, et al. Among authors: young rj. Int J Cancer. 2014 Aug 15;135(4):887-95. doi: 10.1002/ijc.28727. Epub 2014 Jan 30. Int J Cancer. 2014. PMID: 24436120 Free article.
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
Young RJ, Waldeck K, Martin C, Foo JH, Cameron DP, Kirby L, Do H, Mitchell C, Cullinane C, Liu W, Fox SB, Dutton-Regester K, Hayward NK, Jene N, Dobrovic A, Pearson RB, Christensen JG, Randolph S, McArthur GA, Sheppard KE. Young RJ, et al. Pigment Cell Melanoma Res. 2014 Jul;27(4):590-600. doi: 10.1111/pcmr.12228. Epub 2014 Mar 6. Pigment Cell Melanoma Res. 2014. PMID: 24495407 Clinical Trial.
726 results